Tyrosine / fetma

Comprehensive pharmacologic therapy for treatment of obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side

Comprehensive pharmacologic therapy for treatment of obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

REFERENCES Safer than Phen-Fen (copyright 1997), Written by Michael Anchors, MD Ph.D. Pulmonary Vascular Disease, Medical Clinics of North America Nov. 6. 1997, Written by Donald Heath, MD Ph.D. The "Phen-pro" Diet Drug Combination Is Not Associated with Valvular Heart Disease. Jan. 12, 1998

Comprehensive pharmacologic therapy for treatment of obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

REFERENCES Safer than Phen-Fen (copyright 1997), Written by Michael Anchors, MD Ph.D. Pulmonary Vascular Disease, Medical Clinics of North America Nov. 6, 1997, Written by Donald Heath, MD Ph.D. The "Phen-pro" Diet Drug Combination Is Not Associated with Valvular Heart Disease. Jan. 12, 1998

Comprehensive pharmacologic therapy for treatment of obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side

Comprehensive pharmacologic therapy for treatment of obesity including cysteine

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side

Comprehensive pharmacologic therapy for treatment of obesity including cysteine

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

SEQUENCE LISTING The sequence listing submitted via EFS, in compliance with 37 CFR .sctn.1.52(e)(5), is incorporated herein by reference. The sequence listing text file submitted via EFS contains the file "SequenceListing6USCNT3," created on Feb. 17, 2010, which is 341,760 bytes in size. FIELD OF

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn.371 of International Patent Application No. PCT/KR2011/004836 filed Jul. 1, 2011 and published on Apr. 12, 2012 as International Patent Application Publication No. WO2012/046945,

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

TECHNICAL FIELD The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a

Method and composition for treating obesity, drug abuse, and narcolepsy

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to compositions comprising a norepinephrine precursor, such as L-tyrosine or L-phenylalanine in combination with a norepinephrine re-uptake inhibitor such as desipramine. The compositions are useful in controlling obesity, depression, drug abuse, and

Modulators of protein tyrosine phosphatases (PTPases)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to novel thienopyridines, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors

Modulators of protein tyrosine phosphateses (PTPases)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

Modulators of Protein Tyrosine Phosphatases (PTPases)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

tyrosine/fetma

Comprehensive pharmacologic therapy for treatment of obesity

Comprehensive pharmacologic therapy for treatment of obesity

Comprehensive pharmacologic therapy for treatment of obesity

Comprehensive pharmacologic therapy for treatment of obesity

Comprehensive pharmacologic therapy for treatment of obesity including cysteine

Comprehensive pharmacologic therapy for treatment of obesity including cysteine

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Pharmaceutical and food compositions for preventing or treating diabetes or obesity

Method and composition for treating obesity, drug abuse, and narcolepsy

Modulators of protein tyrosine phosphatases (PTPases)

Modulators of protein tyrosine phosphateses (PTPases)

Modulators of Protein Tyrosine Phosphatases (PTPases)

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen